---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-003906"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T03:51:04.282085+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Roivant reports preliminary Q3 cash ~$1.5B; VTAMA revenue guided $9.0-9.5M

## Summary
- Cash, cash equivalents and restricted cash ~$1.5B at Dec 31, 2022; pro-forma $1.7B after expected $115M Myovant proceeds.
- Net product revenues from VTAMA expected $9.0M to $9.5M for Q3 ending Dec 31, 2022.
- Myovant transaction with Sumitomo Pharma expected to close by March 31, 2023.
- Preliminary unaudited results; final Q3 2022 financials to be reported in subsequent SEC filing.

## SEC filing metadata
- accession: 0001140361-23-003906
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/0001140361-23-003906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/ny20006513x3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-003906
- JSON: https://secwatch.observer/filing/0001140361-23-003906.json
- Plain text: https://secwatch.observer/filing/0001140361-23-003906.txt

## Key facts
- Earnings Releases
  Roivant Sciences Ltd. reported the third quarter ended December 31, 2022 results: revenue between $9.0 million and $9.5 million.
  - Period: the third quarter ended December 31, 2022
  - Revenue: between $9.0 million and $9.5 million
  - Result: preliminary results
  source text: In addition, for the third quarter ended December 31, 2022, the Company expects to report between $9.0 million and $9.5 million in net product revenues from VTAMA. This information is preliminary and unaudited and reflects the Company’s estimated financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/0001140361-23-003906-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.